STRO

Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering

Retrieved on: 
Tuesday, April 2, 2024
BofA Securities, SAN, Research, Sale, STRO, Public expenditure, Attention, Security (finance), Spacecraft, Prospectus, Investment

SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the pricing of an underwritten offering of 14,478,764 shares of its common stock at a price of $5.18 per share.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the pricing of an underwritten offering of 14,478,764 shares of its common stock at a price of $5.18 per share.
  • The gross proceeds from this offering are expected to be approximately $75.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Sutro.
  • All of the shares of common stock are being offered by Sutro.
  • The offering is expected to close on or about April 4, 2024, subject to the satisfaction of customary closing conditions.

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

Retrieved on: 
Tuesday, April 2, 2024
ADR, Patient, SAN, SVP, Research, STRO, Cancer, IPN, Spacecraft, IND, Investigational New Drug, Development, ADC, Medicine

Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-drug conjugate, completing the final stages of pre-clinical development

Key Points: 
  • Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-drug conjugate, completing the final stages of pre-clinical development
    PARIS, FRANCE; SAN FRANCISCO, U.S., 02 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) and Sutro Biopharma (NASDAQ: STRO, “Sutro”, “the Company”) today announced an exclusive global licensing agreement for STRO-003.
  • “The potential for ADCs in oncology is well-documented and we are excited by the addition of STRO-003, Ipsen’s first ADC candidate with best-in-class potential.” said Mary Jane Hinrichs, SVP and Head of Early Development at Ipsen.
  • “STRO-003 is a next-generation ROR1 ADC, leveraging Sutro’s site-specific technology to generate a highly stable conjugate, coupled with exatecan payloads, that have shown significant potential in solid tumors.
  • Payloads are the pharmaceutically active component to treat the cancer, attached to the antibody via a chemical linker.

Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones

Retrieved on: 
Monday, March 25, 2024
CBFA2T3, Endometrial cancer, NSCLC, ASH, AML, International, Part, Patient, SAN, STRO, Acute myeloid leukemia, Cancer, Spacecraft, Lung cancer, RAM, PROC, Investment, Phenotype, Society, ADC, Hematology, Nursing

SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the full year 2023, its recent business highlights, and a preview of select anticipated milestones.

Key Points: 
  • “The year 2023 was pivotal for Sutro, with the initiation of REFRαME-O1, our registration-directed study of luvelta for platinum-resistant ovarian cancer (PROC) patients, further validating our next-generation ADC capabilities.
  • The registration-directed trial, REFRαME-O1, for treatment of PROC is enrolling, with an anticipated ~140 sites in ~20 countries to be opened by the end of 2024.
  • Upon exercising the option, Vaxcyte paid Sutro $50 million and is obligated to pay Sutro an additional $25 million within six months.
  • Upon the occurrence of certain regulatory milestones, Vaxcyte would be obligated to pay Sutro up to an additional $60 million.

Sutro Biopharma to Participate in Upcoming Investor Conferences

Retrieved on: 
Tuesday, February 6, 2024
Spacecraft, SAN, STRO, News

SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in three upcoming investor conferences.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in three upcoming investor conferences.
  • Webcasts of the presentations will be accessible through the News & Events page of the Investor Relations section of the company’s website at www.sutrobio.com.
  • Archived replays will be available for at least 30 days after the event.

Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC

Retrieved on: 
Thursday, January 4, 2024
CBFA2T3, Lung cancer, ESMO, Division, Woman, IND, Ovarian cancer, Drug discovery, PD-1, PROC, Spacecraft, Neutropenia, SAN, Gynecologic Oncology (journal), RAM, Endometrial cancer, Q&A, STRO, University, ASH, Bevacizumab, Patient, Phenotype, Acute myeloid leukemia, Safety, Webcast, ADC, NSCLC, AML, Birth control

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), is hosting an investor webcast today highlighting the significant potential of luveltamab tazevibulin (luvelta), a novel folate receptor-α (FolRα) targeting ADC. The presentation will include an overview of the clinical data supporting luvelta’s broad opportunity to address the unmet need in several FolRα-expressing cancers, including platinum-resistant ovarian cancer (PROC), endometrial cancer, CBFA2T3::GLIS2 (CBF/GLIS; RAM phenotype) acute myeloid leukemia (AML), and non-small cell lung cancer (NSCLC).

Key Points: 
  • “Luvelta has been studied in over 180 patients to-date, and has demonstrated both promising clinical activity and a tolerable safety profile.
  • We are optimistic about its potential to change the cancer treatment landscape,” said Bill Newell, Sutro’s Chief Executive Officer.
  • “This includes the potential to be the first ADC to treat ovarian cancer patients with low to medium FolRα expression, which could double the current eligible patient population relative to the FolRα-targeting ADC on the market.
  • Sutro management and Dr. Monk will participate in a Q&A session at the end of the presentation.

Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024

Retrieved on: 
Thursday, December 14, 2023
CBFA2T3, Lung cancer, Ovarian cancer, Spacecraft, PROC, SAN, RAM, Endometrial cancer, Q&A, STRO, Cancer, Webcast, Patient, Phenotype, Acute myeloid leukemia, ADC

The live webcast will be held on Thursday, January 4, 2024, starting at 1:30 p.m. PT / 4:30 p.m.

Key Points: 
  • The live webcast will be held on Thursday, January 4, 2024, starting at 1:30 p.m. PT / 4:30 p.m.
  • ET featuring presentations by members of Sutro’s senior management team and external key opinion leaders in oncology; and concluding with a Q&A session.
  • To access the live audio webcast on Thursday, January 4, at 1:30 p.m. PT / 4:30 p.m.
  • ET, please go to https://ir.sutrobio.com/news-events/ir-calendar
    An archived replay of the webcast will be available on the Company’s website following the live presentation.

Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit

Retrieved on: 
Monday, December 4, 2023
News, Spacecraft, STRO, Hematology, SAN

SOUTH SAN FRANCISCO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on Wednesday, December 6, 2023 at 2:30 p.m.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on Wednesday, December 6, 2023 at 2:30 p.m.
  • ET / 11:30 a.m. PT.
  • A webcast of the fireside chat will be accessible through the News & Events page of the Investor Relations section of the company’s website at www.sutrobio.com.
  • An archived replay will be available for at least 30 days after the event.

Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates

Retrieved on: 
Monday, November 27, 2023
STRO, PCV, Lead, SAN, Key, Pharmaceutical industry

SAN CARLOS, Calif. and SOUTH SAN FRANCISCO, Calif., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Vaxcyte) (NASDAQ: PCVX) and Sutro Biopharma, Inc. (Sutro) (NASDAQ: STRO) today announced that Vaxcyte has exercised its option and entered into a manufacturing rights agreement with Sutro to obtain control over the development and manufacture of cell-free extract, a key component of Vaxcyte’s pneumococcal conjugate vaccine (PCV) franchise, which includes VAX-24 and VAX-31. Pursuant to the manufacturing rights agreement, Vaxcyte obtained exclusive rights to independently, or through certain third parties, develop, improve and manufacture cell-free extract for use in connection with the Company’s vaccine candidates.

Key Points: 
  • Pursuant to the manufacturing rights agreement, Vaxcyte obtained exclusive rights to independently, or through certain third parties, develop, improve and manufacture cell-free extract for use in connection with the Company’s vaccine candidates.
  • “As we advance our lead PCV candidate, VAX-24, into late-stage clinical development, exercising the option to establish a manufacturing rights agreement with Sutro enables us to have full control over the development and manufacturing of cell-free extract for our vaccine candidates,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte.
  • “Over the past year, Vaxcyte has made significant progress with its VAX-24 clinical program, reporting positive results for two Phase 2 studies in adults.
  • Upon the occurrence of certain regulatory milestones, Vaxcyte would be obligated to pay Sutro certain additional milestone payments totaling up to $60 million in cash.

Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer

Retrieved on: 
Tuesday, November 21, 2023
Pharmacia, Science, Cancer, Pharmacy, Commercial, AstraZeneca, Spacecraft, Health, SAN, Columbia University, STRO, Genentech, Growth, Patient, ADC, Onyx, Nursing

SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the promotion of Jane Chung to President and Chief Operating Officer, a newly created role, effective December 1, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the promotion of Jane Chung to President and Chief Operating Officer, a newly created role, effective December 1, 2023.
  • In this newly created position, Ms. Chung will be responsible for driving operational excellence, strategic growth, and overall business success at Sutro.
  • “I am pleased to promote Jane into the leadership position created to optimize business operations at Sutro, expanding her role beyond the Commercial function.
  • “During her time at Sutro, Jane has demonstrated her invaluable strategic thinking skills and collaborative nature, making her the ideal candidate for this role.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Sutro Biopharma, Inc. (NASDAQ: STRO) and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, November 11, 2023
Acquisition, STRO

Kaskela Law LLC announces that it is investigating Sutro Biopharma, Inc. (NASDAQ: STRO) (“Sutro”) on behalf of the company’s investors.

Key Points: 
  • Kaskela Law LLC announces that it is investigating Sutro Biopharma, Inc. (NASDAQ: STRO) (“Sutro”) on behalf of the company’s investors.
  • Sutro stockholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.
  • Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis.
  • For additional information about Kaskela Law LLC please visit www.kaskelalaw.com .